Intervention
Obicetrapib 10 mg
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 2 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
2 shownRandomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's DiseaseNCT07794670 · 2026-09-01
RECRUITINGA Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic SyndromeNCT07219602 · 2025-12-11
ACTIVE_NOT_RECRUITINGCommon conditions
Leading sponsors
Trial status mix
ACTIVE_NOT_RECRUITING1
RECRUITING1
Phase mix
PHASE21
PHASE31
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.